• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Asian Journal of Andrology >The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer
【2h】

The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer

机译：前列腺特异性膜抗原（PSMA）PET-CT在高风险前列腺癌患者中的新兴作用：在高风险前列腺癌中移动酒吧

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The proPSMA trial is a Phase III multicentric trial that examined the role of gallium-68-prostate-specific membrane antigen (PSMA)-positron emission tomography/computed tomography (PET/CT) scan versus conventional CT and bone scan to determine the presence of distant disease prior to curative-intent treatment with surgery or radiation for men with high-risk prostate cancer. The findings showed the superiority of PSMA PET/CT scan with 27% better accuracy and sensitivity at 92% versus conventional CT and bone scans, which yielded 65% (P < 0.0001). Further subgroup analyses showed that PSMA PET-CT was better in detecting pelvic nodal metastases at 91% versus 59% (32% absolute difference; 28%–35%), and in detecting distant metastases at 95% versus 74% (22% absolute difference; 18%–26%). In addition, the use of gallium-68-PET/CT scan also led to changes in the management of patients for curative intent surgery or radiation. In summary, the role of gallium-68-PET/CT scan has evolved and is very promising in the primary staging of high-risk prostate cancer.
机译：ProPsma试验是III期多中心试验，检查了镓-68-前列腺特异性膜抗原（PSMA）-Postron排放断层扫描/计算断层扫描（PET / CT）扫描与常规CT和骨扫描以确定存在的作用远处疾病在治疗意图治疗手术或辐射，用于高危前列腺癌的男性。结果表明，PSMA PET / CT扫描的优越性在92％与常规CT和骨扫描中具有27％的精度和敏感性，其产生65％（P <0.0001）。进一步的亚组分析表明，PSMA PET-CT在检测骨盆节点转移时较好地检测91％，而59％（32％绝对差; 28％-35％），并且在95％的远处转移与74％（22％绝对）差异; 18％-26％）。此外，使用镓-68-PET / CT扫描也导致了治疗意图手术或辐射患者管理的变化。总之，镓-68-PET / CT扫描的作用已经发展，并且在高风险前列腺癌的主要分期中非常有前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号